Liver-compromised diseases such as NAFLD patients were reported to have elevated FFAs in comparison with the healthy group, which is a sign of increased insulin levels and its associated reduced lipolysis with resultant significantly higher FFAs in the bloodstream [93]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.